NovoCure (NVCR) Cash from Operations (2014 - 2026)

NovoCure has disclosed Cash from Operations across 13 years of filings, most recently posting 13517000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 13517000.0, up 62.1% year-over-year; the trailing twelve-month figure through Mar 2026 was 26883000.0 (up 11.74% YoY), and the FY2025 annual result was 49031000.0, down 85.94% from the prior year.
• Cash from Operations came in at 13517000.0 for Q1 2026 at NovoCure, up from 18004000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 22420000.0 in Q3 2022 to a low of 35665000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 13517000.0 (2026), against an average of 7733235.29.
• Across the five-year window, Cash from Operations soared 153.72% in 2024 and sank 826.51% in 2025, its largest moves.
• NovoCure's Cash from Operations stood at 3707000.0 in 2022, then sank by 292.72% to 14558000.0 in 2023, then surged by 76.29% to 3451000.0 in 2024, then plunged by 421.7% to 18004000.0 in 2025, then advanced by 24.92% to 13517000.0 in 2026.
• The last three Cash from Operations figures came in at 13517000.0 (Q1 2026), 18004000.0 (Q4 2025), and 20574000.0 (Q3 2025), per Business Quant data.